AMPK is a known target for treating metabolic syndrome and type-2 diabetes; however, recently AMPK is emerging as a possible metabolic tumor suppressor and target for cancer prevention and treatment. The gene discussed is PRKAA2; the disease is type 2 diabetes mellitus.